These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 9199708

  • 21. Functional cross-reactivity between the glycoprotein B of herpes simplex virus type 1 and Epstein-Barr virus.
    Chan WL.
    Immunology; 1989 Jan; 66(1):14-9. PubMed ID: 15493256
    [Abstract] [Full Text] [Related]

  • 22. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
    Chang YJ, Jiang M, Lubinski JM, King RD, Friedman HM.
    Vaccine; 2005 Sep 07; 23(38):4658-65. PubMed ID: 15936852
    [Abstract] [Full Text] [Related]

  • 23. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.
    Krawczyk A, Krauss J, Eis-Hübinger AM, Däumer MP, Schwarzenbacher R, Dittmer U, Schneweis KE, Jäger D, Roggendorf M, Arndt MA.
    J Virol; 2011 Feb 07; 85(4):1793-803. PubMed ID: 21123390
    [Abstract] [Full Text] [Related]

  • 24. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge.
    Jamali A, Roostaee MH, Soleimanjahi H, Ghaderi Pakdel F, Bamdad T.
    Comp Immunol Microbiol Infect Dis; 2007 Mar 07; 30(2):71-80. PubMed ID: 17126902
    [Abstract] [Full Text] [Related]

  • 25. The effect of DNA priming-protein boosting on enhancing humoral immunity and protecting mice against lethal HSV infections.
    Soleimanjahi H, Roostaee MH, Rasaee MJ, Mahboudi F, Kazemnejad A, Bamdad T, Zandi K.
    FEMS Immunol Med Microbiol; 2006 Feb 07; 46(1):100-6. PubMed ID: 16420602
    [Abstract] [Full Text] [Related]

  • 26. Protective immunization of mice with specific HSV-1 glycoproteins.
    Chan WL.
    Immunology; 1983 Jun 07; 49(2):343-52. PubMed ID: 6303950
    [Abstract] [Full Text] [Related]

  • 27. Innate and acquired immunity to herpes simplex virus type 1.
    Halford WP, Veress LA, Gebhardt BM, Carr DJ.
    Virology; 1997 Sep 29; 236(2):328-37. PubMed ID: 9325240
    [Abstract] [Full Text] [Related]

  • 28. Alterations in the antigenic structure of two major HSV-1 glycoproteins, gC and gB, influence immune regulation and susceptibility to murine herpes keratitis.
    Hendricks RL, Tao MS, Glorioso JC.
    J Immunol; 1989 Jan 01; 142(1):263-9. PubMed ID: 2909617
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Proliferative T-cell response to glycoprotein B of the human herpes viruses: the influence of MHC and sequence of infection on the pattern of cross-reactivity.
    Chan WL, Tizard ML, Faulkner L.
    Immunology; 1989 Sep 01; 68(1):96-101. PubMed ID: 2553584
    [Abstract] [Full Text] [Related]

  • 31. [Envelope and membrane glycoproteins of Herpes simplex virus].
    Ramos-Kuri JM.
    Rev Latinoam Microbiol; 1992 Sep 01; 34(1):23-31. PubMed ID: 1345300
    [Abstract] [Full Text] [Related]

  • 32. Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice.
    Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, Ebtekar M.
    Comp Immunol Microbiol Infect Dis; 2007 Jul 01; 30(4):197-210. PubMed ID: 17335902
    [Abstract] [Full Text] [Related]

  • 33. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F, Soleimanjahi H, Roostaee MH, Behzadian F.
    FEMS Immunol Med Microbiol; 2008 Oct 01; 54(1):18-26. PubMed ID: 18647350
    [Abstract] [Full Text] [Related]

  • 34. Use of monoclonal antibodies to HSV-1 and HSV-2 for serological analysis of the viral glycoproteins.
    Pereira L.
    Dev Biol Stand; 1982 Oct 01; 52():115-31. PubMed ID: 6299824
    [Abstract] [Full Text] [Related]

  • 35. Glycoprotein gB of herpes simplex virus expresses type-common and type-specific antigenic determinants in vivo.
    Dix RD.
    J Med Virol; 1990 Mar 01; 30(3):192-5. PubMed ID: 1692872
    [Abstract] [Full Text] [Related]

  • 36. Epitope mapping of herpes simplex virus type 2 gH/gL defines distinct antigenic sites, including some associated with biological function.
    Cairns TM, Shaner MS, Zuo Y, Ponce-de-Leon M, Baribaud I, Eisenberg RJ, Cohen GH, Whitbeck JC.
    J Virol; 2006 Mar 01; 80(6):2596-608. PubMed ID: 16501070
    [Abstract] [Full Text] [Related]

  • 37. Human antibodies to herpes simplex virus type 1 glycoprotein C are neutralizing and target the heparan sulfate-binding domain.
    Adamiak B, Trybala E, Mardberg K, Johansson M, Liljeqvist JA, Olofsson S, Grabowska A, Bienkowska-Szewczyk K, Szewczyk B, Bergstrom T.
    Virology; 2010 May 10; 400(2):197-206. PubMed ID: 20176392
    [Abstract] [Full Text] [Related]

  • 38. Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge.
    Clementi N, Criscuolo E, Cappelletti F, Quaranta P, Pistello M, Diotti RA, Sautto GA, Tarr AW, Mailland F, Concas D, Burioni R, Clementi M, Mancini N.
    Antiviral Res; 2017 Jul 10; 143():48-61. PubMed ID: 28396205
    [Abstract] [Full Text] [Related]

  • 39. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response.
    Mitchell BM, Stevens JG.
    J Immunol; 1996 Jan 01; 156(1):246-55. PubMed ID: 8598469
    [Abstract] [Full Text] [Related]

  • 40. Protective efficacy of neutralizing antibodies against Ebola virus infection.
    Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y.
    Vaccine; 2007 Jan 22; 25(6):993-9. PubMed ID: 17055127
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.